Chronic Refractory Breathlessness

Definition

Chronic breathlessness syndrome is breathlessness that persists despite optimal treatment of the underlying cause, and that results in disability. Two elements define it: the underlying disease has genuinely been optimised, and the symptom persists. The word “refractory” refers to the disease-directed treatment, not to the symptom — the symptom itself responds to a range of interventions, which is the central point of this page.

Formal recognition as a syndrome was a deliberate act: naming it makes it a target for treatment, a subject for research and a reason for referral, rather than an inevitable feature of advanced disease that no one is responsible for addressing.¹

What it is not

• Not undertreated disease. Optimisation has to be real — correct inhaler technique, current heart failure therapy, anaemia and thyroid function checked. Labelling breathlessness refractory before that is a diagnostic failure.
• Not acute breathlessness, which is a different clinical problem needing urgent assessment.
• Not “just anxiety”. Anxiety is genuinely part of the mechanism, but it amplifies a real physiological signal rather than inventing one.
• Not confined to the end of life. It occurs across the course of chronic disease, and treating it early is more effective than treating it late.

Pathophysiology

Breathlessness is generated in the brain

The sensation arises when the brain detects a mismatch between the drive to breathe and the feedback it receives about what the body actually achieved. That mismatch — neuromechanical dissociation — explains why breathlessness correlates poorly with lung function or oxygen level: a normal saturation does not mean the drive to breathe is being satisfied. It also explains why interventions that change perception, rather than mechanics, can be effective.

The breathing–thinking–functioning cycle

Three self-reinforcing loops maintain the symptom, and each offers a point of intervention:

The model matters practically: it explains why a single intervention rarely works and why the combination is more effective than the sum of its parts.²

Why a fan works

Stimulating the trigeminal nerve distribution — airflow across the face — alters the central perception of breathlessness. It is not a placebo effect, it is fast, it costs almost nothing, and it is among the best-supported non-drug interventions available.

Co-morbidities

• The underlying disease — most often COPD, heart failure, interstitial lung disease or lung cancer; frequently more than one.
• Anxiety and panic — present in a large proportion, and both a consequence and an amplifier.
• Depression — common, under-recognised, and a barrier to engaging with rehabilitation.
• Deconditioning and sarcopenia — the most modifiable contributor, and often the largest.
• Dysfunctional breathing patterns — frequently superimposed; see dysfunctional breathing.
• Obesity or malnutrition — both increase the work of breathing, by different routes.
• Carer strain and social isolation — part of the clinical picture, not background to it.

Prevalence

Chronic breathlessness affects a large share of people with advanced cardiorespiratory disease — the majority in advanced COPD and in advanced heart failure — and a meaningful proportion of older people in the community, many of whom have never been assessed for it. It is systematically under-reported: patients attribute it to ageing or to their diagnosis, adapt their lives around it, and do not raise it because they assume nothing can be done.³

Causes

The syndrome is defined by persistence despite optimised disease treatment, but several contributors are commonly missed at that optimisation stage and are worth checking before accepting the label:

• Inhaler technique — a substantial proportion of patients derive little benefit from correctly prescribed inhalers because of technique. See inhaler technique.
• Anaemia, thyroid disease, and deconditioning — all treatable, all frequently overlooked.
• Coexisting cardiac disease in a respiratory patient, or the reverse.
• Pulmonary hypertension — suspect where breathlessness exceeds what the lung disease explains.
• Medication — beta-blocker intolerance, fluid overload, sedation.
• Untreated anxiety or panic disorder.

Symptoms

How it presents

• Breathlessness on progressively less exertion, and eventually at rest in some patients.
• Episodic surges — sudden, frightening intensification, often with a clear trigger, sometimes without.
• Fear, and in some cases panic, during episodes.
• A steadily shrinking range of activity, often concealed by avoidance rather than reported.
• Fatigue, poor sleep and low mood.
• Withdrawal from social activity, and loss of role at home and at work.

Warning signs

Diagnosis

Establishing the syndrome

There is no test. The diagnosis is made by confirming that the underlying disease is genuinely optimised, that the breathlessness is persistent rather than acute, and that it is causing disability. The last element is what turns a symptom into a treatment target.

Measuring it

• The mMRC scale — grades what the breathlessness stops the person doing; simple and widely used.
• A numerical rating or visual analogue scale — captures intensity now, at worst, and on average, and is responsive to change.
• The Chronic Respiratory Questionnaire or Dyspnoea-12 — separate the physical and emotional dimensions, which respond differently to treatment.
• A field walking test with oximetry — objective capacity and exertional desaturation.
• Anxiety and depression screening — because both are treatable contributors.

Measuring matters more here than in most conditions: unmeasured breathlessness is routinely under-treated, and a recorded score is what makes change visible to both patient and clinician.

Management

Non-drug first, and it is not second-best

Drug treatment

Low-dose sustained-release oral morphine reduces breathlessness in some patients with severe chronic breathlessness, and is recommended in several guidelines for carefully selected cases with monitoring, dose titration and prophylactic management of constipation. The evidence is more mixed than it was once thought — a large recent trial in COPD was negative — so it is best framed as an individual trial with a clear stopping rule rather than a standard step. Benzodiazepines are not supported as first-line treatment. Supplemental oxygen relieves breathlessness only in patients who are hypoxaemic; in non-hypoxaemic patients a fan performs as well.⁴

Living with chronic breathlessness

Naming it changes the conversation

Many people have been told that their disease is as well treated as it can be, and have heard that as nothing more can be done. Separating the disease from the symptom — and being clear that the symptom has its own treatments — is often the most useful conversation in the whole consultation.

Having a plan for episodes

A written, rehearsed plan — position, fan, breathing pattern, when to seek help — reduces the fear that drives the cycle. Rehearsing it when calm is what makes it usable when not.

Family and carers

Watching someone struggle to breathe is frightening, and carers frequently encourage rest, which worsens deconditioning. Involving them in the explanation and the plan changes what happens at home more than instructions given to the patient alone.

Expanding, not just coping

The aim is not only to tolerate breathlessness but to get activity back. Patients who understand that breathlessness during exercise is safe do more, and doing more is what reduces it.

Prognosis

The syndrome usually persists, because the underlying disease persists. What changes with treatment is the disability: mastery, activity level, distress and quality of life all improve with rehabilitation and with a structured breathlessness intervention, often substantially, even when the breathlessness score itself moves modestly. Untreated, the trajectory is progressive withdrawal, deconditioning and isolation — which is a preventable outcome rather than an inevitable one.

Role of the physiotherapist

Central, not adjunctive

Almost every effective non-drug intervention in this syndrome is delivered by physiotherapy. In most services the physiotherapist is the clinician who assesses the symptom in detail, prescribes the exercise, teaches the techniques and builds the plan — which makes this one of the conditions where the profession contributes most.

Assessment

Measure breathlessness with a validated tool at rest, on exertion and at its worst; establish what has already been given up, which is usually more than the patient volunteers; assess exercise capacity and desaturation on a field test; observe the breathing pattern at rest and after effort; and screen for anxiety. Record a baseline — without one, improvement is invisible.

Exercise training

The core intervention. Prescribe at a symptom-limited intensity, use interval formats where needed, include resistance work, and be explicit that breathlessness during training is expected and safe. Address the fear directly: patients who believe breathlessness is harmful will not train hard enough to benefit.

Techniques and equipment

Breathing control, pursed-lip breathing, positioning, the fan, energy conservation, and a rehearsed episode plan. See managing breathlessness for the patient-facing version of these techniques, and your plan for managing your condition.

Knowing when to escalate

Refer on where breathlessness is disproportionate to the known disease, where anxiety or depression dominates, where a specialist breathlessness service exists, or where the symptom is severe enough that a drug trial should be considered. Equally, recognise an acute change: a step-change in a chronic symptom is a new clinical problem, and treating it as a technique failure is the error to avoid.

Part 1 · References

1. Johnson MJ, Yorke J, Hansen-Flaschen J, et al. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. Eur Respir J 2017;49(5):1602277.
2. Spathis A, Booth S, Moffat C, et al. The Breathing, Thinking, Functioning clinical model: a proposal to facilitate evidence-based breathlessness management. NPJ Prim Care Respir Med 2017;27(1):27.
3. Currow DC, Plummer JL, Crockett A, Abernethy AP. A community population survey of prevalence and severity of dyspnea in adults. J Pain Symptom Manage 2009;38(4):533–545.
4. Ekström M, Ferreira D, Chang S, et al. Effect of regular, low-dose, extended-release morphine on chronic breathlessness in chronic obstructive pulmonary disease: the BEAMS randomized clinical trial. JAMA 2022;328(20):2022–2032.

References are numbered in citation order (Vancouver/BMJ style) and were current at the time of writing. Guidelines are living documents — verify against the latest version before clinical use.